Liminatus Pharma is a immuno‑oncology company offering CD47‑blockade antibody solutions to prevent anemia and thrombocytopenia.
Liminatus Pharma has raised $1.9M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
Liminatus Pharma's investors include Capital Trust Group.
Liminatus Pharma is headquartered in Wilmington, United States.
Liminatus Pharma is a immuno‑oncology company offering CD47‑blockade antibody solutions to prevent anemia and thrombocytopenia.
Liminatus Pharma is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Liminatus Pharma — Funding & Investors." VCBacked, June 3, 2026, https://www.vcbacked.co/company/liminatus-pharma. Accessed September 30, 2026.
VCBacked. (2026). Liminatus Pharma — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/liminatus-pharma
{{cite web |title=Liminatus Pharma — Funding & Investors |url=https://www.vcbacked.co/company/liminatus-pharma |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated